@Uniformed_ReRe - check the credentials on who did this study…consensus is falling apart.
Students at North American universities risk disenrollment due to third dose COVID-19 vaccine mandates. We present a risk-benefit assessment of boosters in this
deliverypdf.ssrn.com
704 7. Conclusion
705 Based on public data provided by the CDC18, we estimate that approximately 22,000 to 30,000
706 previous uninfected young adults ages 18–29 years must be boosted with an mRNA vaccine to
707 prevent one Covid-19 hospitalisation. Given the fact that this estimate does not take into
708 account the protection conferred by prior infection nor a risk-adjustment for comorbidity status,
709 this should be considered a conservative and optimistic assessment of benefit. Our estimate
710 shows that university Covid-19 vaccine mandates are likely to cause net expected harms to
711 young healthy adults—between 18 and 98 serious adverse events requiring hospitalisation and
712 1373 to 3234 disruptions of daily activities—that is not outweighed by a proportionate public
713 health benefit. Serious Covid-19 vaccine-associated harms are not adequately compensated for
714 by current US vaccine injury systems. As such, these severe infringements of individual liberty
715 are ethically unjustifiable.
716
31
This preprint research paper has not been peer reviewed. Electronic copy available at:
https://ssrn.com/abstract=4206070
Preprint not peer reviewed
717 Worse still, mandates are associated with wider social harms. The fact that such policies were
718 implemented despite controversy among experts and without updating the sole publicly
719 available risk-benefit analysis to the current Omicron variants suggests a profound lack of
720 transparency in scientific and regulatory policy making. These findings have implications for
721 mandates in other settings such as schools, corporations, healthcare systems and the military.
722 Policymakers should repeal booster mandates for young adults immediately, ensure pathways
723 to compensation to those who have suffered negative consequences from these policies,
724 provide open access to participant-level clinical trial data to allow risk- and age-stratified harm-
725 benefit analyses of any new vaccines prior to issuing recommendations125, and begin what will
726 be a long process of rebuilding trust in public health.
727 728
729 Conflicts of Interest
730 We have no interests to declare.
